Key result
Optimizing heart failure therapies, reducing subclinical congestion, and ensuring optimal care transitions are essential to improve outcomes in acute heart failure.
Optimizing disease-modifying therapies and ensuring optimal transitions of care after discharge are essential to improve outcomes in acute heart failure.
Advocates individualized AHF therapy accounting for comorbidities and ethics; leaves open validation in prospective trials.
Acute heart failure (AHF) is a life-threatening condition requiring immediate treatment. The initial therapy should take into account the clinical presentation, pathophysiology at play, precipitating factors and underlying cardiac pathology. Particular attention should be given to polymorbidity and the avoidance of potential iatrogenic harm. Patient preferences and ethical issues should be integrated into the treatment plan at an early stage. The average survival of AHF patients is 2 years and the most vulnerable period is the 3-month time window directly after discharge. Reducing both persistent subclinical congestion and underutilisation of disease-modifying heart failure therapies as well as ensuring optimal transitions of care after hospital discharge are essential in improving outcomes for AHF patients.
No takes yet. Share an insight, caveat, or question.
Arrigo et al. (2018) conducted a review in Acute heart failure. Heart failure therapies was evaluated. Optimizing heart failure therapies, reducing subclinical congestion, and ensuring optimal care transitions are essential to improve outcomes in acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: